R 1549
Alternative Names: Monoclonal antibody HMFG1 yttrium 90 labelled; Pemtumomab; R1549; Theragyn; Yttrium 90 labelled monoclonal antibody HMFG1Latest Information Update: 20 Sep 2004
At a glance
- Originator Cancer Research UK
- Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Immunomodulators; Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gastric cancer; Ovarian cancer
Most Recent Events
- 20 Sep 2004 Discontinued - Phase-II for Gastric cancer in United Kingdom (Intraperitoneal)
- 20 Sep 2004 Discontinued - Phase-III for Ovarian cancer in Australia (Intraperitoneal)
- 20 Sep 2004 Discontinued - Phase-III for Ovarian cancer in Austria (Intraperitoneal)